Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing …
…, M Majure, E Stringer-Reasor, C Parker… - JAMA …, 2020 - jamanetwork.com
Importance Approximately 25% of patients with early-stage breast cancer who receive (neo)adjuvant
chemotherapy experience a recurrence within 5 years. Improvements in therapy …
chemotherapy experience a recurrence within 5 years. Improvements in therapy …
The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) …
SE Kimmel, Z Chen, M Price, CS Parker… - Archives of internal …, 2007 - jamanetwork.com
Background Warfarin sodium is a highly efficacious drug, but proper levels of anticoagulation
are difficult to maintain. Conflicting data exist on the influence of patient adherence on …
are difficult to maintain. Conflicting data exist on the influence of patient adherence on …
[PDF][PDF] Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer
…, H Parnes, CC Chen, E Jones, CE Parker… - Journal of clinical …, 2004 - researchgate.net
Randomized Phase II Trial of Docetaxel Plus Thalidomide in Androgen-Independent Prostate
Cancer Page 1 Randomized Phase II Trial of Docetaxel Plus Thalidomide in …
Cancer Page 1 Randomized Phase II Trial of Docetaxel Plus Thalidomide in …
Breast cancer screening and diagnosis, version 3.2018, NCCN clinical practice guidelines in oncology
…, CD Lehman, B Monsees, BL Niell, CC Parker… - Journal of the National …, 2018 - jnccn.org
The NCCN Guidelines for Breast Cancer Screening and Diagnosis have been developed to
facilitate clinical decision making. This manuscript discusses the diagnostic evaluation of …
facilitate clinical decision making. This manuscript discusses the diagnostic evaluation of …
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.
PM Arlen, JL Gulley, C Parker, L Skarupa… - Clinical cancer research …, 2006 - AACR
PURPOSE: Docetaxel has activity against androgen-independent prostate cancer and
preclinical studies have shown that taxane-based chemotherapy can enhance antitumor …
preclinical studies have shown that taxane-based chemotherapy can enhance antitumor …
Risk factors for nonadherence to warfarin: results from the IN‐RANGE study
…, JD Christie, R Gross, CS Parker… - … and drug safety, 2008 - Wiley Online Library
Background Warfarin is widely used to prevent stroke and venous thromboembolism despite
its narrow therapeutic window. Warfarin nonadherence is a substantial problem, but risk …
its narrow therapeutic window. Warfarin nonadherence is a substantial problem, but risk …
[HTML][HTML] Prepregnancy and early pregnancy calcium supplementation among women at high risk of pre-eclampsia: a multicentre, double-blind, randomised, placebo …
…, P Njikelana, N Novikova, A Oyebajo, C Parker… - The Lancet, 2019 - thelancet.com
Background Reducing deaths from hypertensive disorders of pregnancy is a global priority.
Low dietary calcium might account for the high prevalence of pre-eclampsia and eclampsia …
Low dietary calcium might account for the high prevalence of pre-eclampsia and eclampsia …
Disparities in the use of breast-conserving therapy among patients with early-stage breast cancer
Importance Although breast-conserving therapy (BCT) is an accepted modality for treatment
of early-stage breast cancer, many women continue to undergo mastectomy. Detailing the …
of early-stage breast cancer, many women continue to undergo mastectomy. Detailing the …
Depression, anxiety, and acute stress disorder among patients hospitalized with COVID-19: a prospective cohort study
Background The epidemiology of psychiatric symptoms among patients with coronavirus
disease 2019 is poorly characterized. Objective This article sought to identify the prevalence of …
disease 2019 is poorly characterized. Objective This article sought to identify the prevalence of …
A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer
…, M Noone, K Fedenko, M Hamilton, C Parker… - Seminars in …, 2001 - Elsevier
New therapeutic alternatives are needed to improve outcomes in patients with androgen-independent
prostate cancer (AIPC). For several years, researchers at the National Cancer …
prostate cancer (AIPC). For several years, researchers at the National Cancer …